ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 5
Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment
Experts discuss regimens with the most favorable toxicity profiles and how they personalize treatment to minimize patient burden, while also exploring preferred strategies for patients who have completed pembrolizumab in the adjuvant setting and how the timing of recurrence relative to adjuvant therapy completion influences treatment selection.
Video Player is loading.
Video content above is prompted by the following:
- What regimens have you found to offer the most favorable toxicity profile? How do you personalize treatment to minimize patient burden?
- What are your preferred strategies for patients who have completed pembrolizumab in the adjuvant setting?
- How does the timing of recurrence relative to adjuvant therapy completion influence your treatment selection?
- Please discuss which patients might still be candidates for initial active surveillance. Which factors prompt you to consider active surveillance rather than immediate systemic therapy?